Skip to main content
Top
Published in: AIDS and Behavior 12/2016

Open Access 01-12-2016 | Original Paper

Quantifying Syringe Exchange Program Operational Space in the District of Columbia

Authors: Sean T. Allen, Monica S. Ruiz, Jeff Jones

Published in: AIDS and Behavior | Issue 12/2016

Login to get access

Abstract

Syringe exchange programs (SEPs) are effective structural interventions for HIV prevention among persons who inject drugs. In 2000, a buffer zone policy (the 1000 Foot Rule) was implemented in Washington, DC, that prohibited SEP operations within 1000 feet of schools. We examined changes in the amount of legal SEP operational space over time. We used data pertaining to school operations and their approximate physical property boundaries to quantify the impact of the 1000 Foot Rule on legal SEP operational space from its implementation in 2000–2013. Adherence to the 1000 Foot Rule reduced SEP operational space by more than 50 % annually since its implementation. These findings demonstrate the significant restrictions on the amount of legal SEP operational space in Washington, DC, that are imposed by the 1000 Foot Rule. Changing this policy could have a significant impact on SEP service delivery among injectors.
Literature
1.
go back to reference Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One. 2014;9(5):e97596.CrossRefPubMedPubMedCentral Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One. 2014;9(5):e97596.CrossRefPubMedPubMedCentral
3.
go back to reference Grigoryan A, Shouse RL, Durant Td, et al. HIV infection among injection–drug users—34 states, 2004–2007. MMWR Morb Mortal Wkly Rep. 2009;58(46):1291–5. Grigoryan A, Shouse RL, Durant Td, et al. HIV infection among injection–drug users—34 states, 2004–2007. MMWR Morb Mortal Wkly Rep. 2009;58(46):1291–5.
4.
go back to reference Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352–8.CrossRefPubMed Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352–8.CrossRefPubMed
9.
go back to reference Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano DD. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort 1988–2000: description and determinants. Am J Epidemiol. 2003;158(7):695–704.CrossRefPubMed Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano DD. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort 1988–2000: description and determinants. Am J Epidemiol. 2003;158(7):695–704.CrossRefPubMed
10.
go back to reference Bammer G, Battisson L, Ward J, Wilson S. The impact on retention of expansion of an Australian public methadone program. Drug Alcohol Depend. 2000;58(1–2):173–80.CrossRefPubMed Bammer G, Battisson L, Ward J, Wilson S. The impact on retention of expansion of an Australian public methadone program. Drug Alcohol Depend. 2000;58(1–2):173–80.CrossRefPubMed
11.
go back to reference Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother. 2002;36(2):312–21.CrossRefPubMed Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother. 2002;36(2):312–21.CrossRefPubMed
12.
go back to reference Simpson DD, Joe GW, Rowan-szal GA. Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend. 1997;47(3):227–35.CrossRefPubMed Simpson DD, Joe GW, Rowan-szal GA. Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend. 1997;47(3):227–35.CrossRefPubMed
13.
go back to reference Des Jarlais DC. Structural interventions to reduce HIV transmission among injecting drug users. AIDS. 2000;14(Suppl 1):S41–6.CrossRefPubMed Des Jarlais DC. Structural interventions to reduce HIV transmission among injecting drug users. AIDS. 2000;14(Suppl 1):S41–6.CrossRefPubMed
14.
go back to reference Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6–7):777–813.CrossRefPubMed Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6–7):777–813.CrossRefPubMed
15.
go back to reference Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997;349(9068):1797–800.CrossRefPubMed Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997;349(9068):1797–800.CrossRefPubMed
16.
go back to reference Kerr T, Small W, Buchner C, et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010;100(8):1449–53.CrossRefPubMedPubMedCentral Kerr T, Small W, Buchner C, et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010;100(8):1449–53.CrossRefPubMedPubMedCentral
17.
go back to reference Ksobiech K. A meta-analysis of needle sharing, lending, and borrowing behaviors of needle exchange program attenders. AIDS Educ Prev. 2003;15(3):257–68.CrossRefPubMed Ksobiech K. A meta-analysis of needle sharing, lending, and borrowing behaviors of needle exchange program attenders. AIDS Educ Prev. 2003;15(3):257–68.CrossRefPubMed
18.
go back to reference Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction. 2010;105(5):844–59.CrossRefPubMed Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction. 2010;105(5):844–59.CrossRefPubMed
24.
go back to reference Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(Suppl 1):S133–8.CrossRefPubMed Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(Suppl 1):S133–8.CrossRefPubMed
31.
go back to reference Allen S, Ruiz MS, O’Rourke A. How far will they go? Assessing the travel distance of current and former drug users to access harm reduction services. Harm Reduct J. 2015;12(1):3.CrossRefPubMedPubMedCentral Allen S, Ruiz MS, O’Rourke A. How far will they go? Assessing the travel distance of current and former drug users to access harm reduction services. Harm Reduct J. 2015;12(1):3.CrossRefPubMedPubMedCentral
Metadata
Title
Quantifying Syringe Exchange Program Operational Space in the District of Columbia
Authors
Sean T. Allen
Monica S. Ruiz
Jeff Jones
Publication date
01-12-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 12/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1405-y

Other articles of this Issue 12/2016

AIDS and Behavior 12/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.